Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment

BACKGROUND AND AIM: Conversion surgery (CS), which aims to cure after systematic therapy, is only scarcely reported in the field of hepatocellular carcinoma (HCC). However, advancements in systemic therapy for HCC are expected to increase the candidates eligible for CS because of the higher response...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneko, Shun, Tsuchiya, Kaoru, Yasui, Yutaka, Tanaka, Yuki, Inada, Kento, Ishido, Shun, Kirino, Sakura, Yamashita, Koji, Hayakawa, Yuka, Nobusawa, Tsubasa, Matsumoto, Hiroaki, Kakegawa, Tatsuya, Higuchi, Mayu, Takaura, Kenta, Tanaka, Shohei, Maeyashiki, Chiaki, Tamaki, Nobuharu, Takahashi, Yuka, Nakanishi, Hiroyuki, Irie, Takumi, Ariizumi, Shun‐Ichi, Kurosaki, Masayuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120872/
https://www.ncbi.nlm.nih.gov/pubmed/35601130
http://dx.doi.org/10.1002/jgh3.12735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120872/
https://www.ncbi.nlm.nih.gov/pubmed/35601130
http://dx.doi.org/10.1002/jgh3.12735

Ejemplares similares